Search
Fexofenadine
go.drugbank.com/drugs/DB00950ApprovedInvestigational[diphenhydramine], which readily bind to off-targets that contribute to side effects such as sedation. … for the H<sub>1</sub> receptor, carries little-to-no activity at off-targets, and does not cross the blood-brain barrier[L10779] - this is in contrast to previous first-generation antihistamines, such as
Cinnamyl alcohol
go.drugbank.com/drugs/DB14186ApprovedDue to the low levels found in cinnamon, cinnamyl alcohol is usually supplied as [DB14184] within commercial products. … Cinnamyl alcohol has been shown to be a skin sensitizer, with a NOEL (No Effect Level) of ~4% [A34266]. Sensitivity to cinnamyl alcohol may be identified with a clinical patch test.
Blinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigational[L44311] Full approval for this indication was granted in June 2023. … Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.
Telisotuzumab vedotin
go.drugbank.com/drugs/DB15104ApprovedInvestigational[L53193] Telizotuzumab vedotin-tllv was approved by the US FDA in May 2025 for previously treated advanced NSCLC patients with high c-Met protein overexpression,[L53158,L53183] becoming the first treatment
Mycophenolic acid
go.drugbank.com/drugs/DB01024ApprovedInvestigational[L42165] It was derived from _Penicillium stoloniferum_, and has also shown antibacterial, antifungal and antiviral properties.[A249170]. … Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone.
Serdexmethylphenidate
go.drugbank.com/drugs/DB16629Approved[L32298, L32323] Serdexmethylphenidate was granted FDA approval on March 2, 2021, and is currently marketed as a combination capsule with [dexmethylphenidate] under the trademark AZSTARYS™ by KemPharm … such as [methylphenidate] and [amphetamine] that increase extracellular dopamine and norepinephrine levels.
Omidenepag isopropyl
go.drugbank.com/drugs/DB15071ApprovedThe use of an EP2 receptor agonist such as omidenepag represents an alternative in these scenarios. Omidenepag IOP-lowering effect is comparable to the one observed with [latanoprost]. … [A253253] In 2018, omidenepag isopropyl was approved in Japan for the treatment of glaucoma and ocular hypertension.[A253268] In September 2022, the FDA approved the use of omidenepag isopropyl.
Egg phospholipids
go.drugbank.com/drugs/DB14233ApprovedWithdrawnEgg phospholipids are available as an intravenous fat emulsion indicated as a source of calories for patients requiring parenteral nutrition.
Levonordefrin
go.drugbank.com/drugs/DB06707ApprovedInvestigationalLevonordefrin acts as a topical nasal decongestant and vasoconstrictor, most often used in dentistry.